Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Coronavirus and the outbreak of the respiratory illness
- COPD 2021

Welcome Message

On behalf of the Organizing Committee, we take great pleasure in welcoming Scientists, Professors, Students and experts who belong to the Pulmonology field for the 8th International Conference on COPD and Lung Health which is scheduled during October 07-08, 2021 in Paris, France.

COPD 2021 unites the worldwide pioneers who are involved in the Pulmonary and respiratory field to explore their research work at the conference. COPD 2021 provides a great chance to collaborate with global business delegates and researchers and it is all set to be adorned by world renowned speakers.

With the successful completion of COPD 2020 hosted by the Allied Academies, which was held during October 19-20, 2020 with the theme “Innovating New Technologies and Therapeutics in The Field of COPD and Lung Health”, we are back with CPD Accredited 8th International Conference on COPD and Lung Health with the theme “Coronavirus and the outbreak of respiratory illness”. The wide range of topics will give attendees a chance to learn about every aspect of COPD and respiratory diseases.

Abstract Submission & Important Dates

Abstract Submission Guidelines: 

Ø  Abstract length must not exceed 300 words.

Ø  The title should be in sentence case.

Ø  Mention the full name of the author and co-authors (if any) along with affiliation.

Ø  It should contain short biography of the author (limited to 100 words) along with the photograph.

Ø All the abstracts will be reviewed by the scientific committee members and you will get an email within 24-48 hours after submission of your abstract.

Ø All the accepted abstracts will be published in the conference proceedings in the respective Journal.

Abstract Submission URL: https://copd.alliedacademies.com/2020/abstract-submission

Registration URL: https://copd.alliedacademies.com/2020/registration

Sessions and Tracks

Sessions and Tracks

Session 1: COPD

Chronic Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage and problems related to breathing. It can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, shortness of breath as well as chest tightness. Cigarette smoking is the leading cause of COPD. Long-term exposure to various lung irritants such as air pollution, chemical fumes, or dusts also contribute to COPD. A rare genetic condition called alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be cured but it can be treated to lower the chance of complications, and generally improve quality of life. Clinical symptoms and signs, such as abnormal shortness of breath and increased forced expiratory time, can be used to help with the diagnosis of COPD. Various forms of treatment include Medications, supplemental oxygen therapy and surgery.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 2: Respiratory Diseases

Respiratory diseases encompass a variety of pathogenic conditions that affect respiration in living organisms. Respiration involves gas exchange in higher organisms. Respiratory disorders occur in the respiratory tract, which includes the alveoli, bronchi, bronchioles, pleura, pleural cavity, trachea and the nerves and muscles of breathing. Respiratory diseases or lung diseases include COPD, asthma, cystic fibrosis, emphysema, lung cancer, interstitial lung disease, mesothelioma, pulmonary hypertension, tuberculosis, alpha-1 antitrypsin deficiency, bronchiectasis, idiopathic pulmonary fibrosis, pneumonia, respiratory failure, respiratory distress syndrome, sarcoidosis, sleep apnea, sleep deprivation and deficiency, influenza and many more. If left untreated, they lead to health complications and life-threatening conditions.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 3: Effect of COVID-19 on Lungs  

COVID-19 is a respiratory disease which causes a range of breathing problems, from mild to critical. Older adults and people who have other health conditions like heart disease, cancer, and diabetes may have more serious symptoms when compared to others. Coronavirus can infect the upper or lower part of the respiratory tract and travels down the airways making the lining become irritated and inflamed. In some cases, the infection can reach all the way down into the alveoli. Respiratory inflammation can be observed on a chest X-ray or CT scan. Currently, convalescent plasma from a recovered patient is given by transfusion to a patient who is suffering from COVID-19. The donor antibodies may help the patient fight the illness, possibly shortening the reducing the severity of the disease.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 4: Tuberculosis

Tuberculosis (TB) is a serious infectious disease that mainly affects the lungs and it is caused by bacteria (Mycobacterium tuberculosis). The bacteria responsible for tuberculosis is spread from one person to another through tiny droplets released into the air via cough and sneeze. Tuberculosis can be fatal when it is untreated. Untreated active disease typically affects the lungs, and it can spread to other parts of the body through the blood stream. Complications of tuberculosis include spinal pain, joint damage, swelling of the membranes that cover the brain, liver or kidney problems and heart disorders. People diagnosed with active TB disease generally have to take a combination of medications for six to nine months. A significant number of TB patients develop post tubercular airway disease or TB-associated COPD.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 5: Asthma

Asthma is a clinical syndrome of chronic airway inflammation characterized by recurrent and reversible airway obstruction. Most people with asthma will not develop COPD, However, it’s possible to have both. Asthma-COPD overlap syndrome (ACOS) occurs when someone has these two diseases at a time. Signs of ACOS include difficulty in breathing, wheezing, frequent coughing, excess phlegm, feeling tired, low physical tolerance for exercise, shortness of breath during routine activities. Common triggers for asthmatic symptoms include exposure to allergens (dust mites, cockroach, molds and pollens), exercise and viral infections. Most people who have asthma are treated with daily medicine, called long-term control medicines, along with inhalers containing medicine for short-term relief.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 6: Pneumonia

Pneumonia is an infection that inflames the air sacs in the lungs and people with COPD are more likely to develop pneumonia. It is most serious for infants, young children and older people whose age is above 65, and people with weakened immune systems. Bacterial pneumonia, is the most common form, tends to be more serious than other types of pneumonia. The symptoms of bacterial pneumonia can develop gradually. In few cases pneumonia can be difficult to diagnose because the symptoms are so variable and are often very similar to those seen in a cold or influenza. Complications of pneumonia are as follows: pleural effusion, empyema, lung abscess, bacteremia, septicemia, meningitis, septic arthritis, endocarditis, or pericarditis.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 7: Sleep Apnea

Sleep apnea is a sleep disorder that occurs when a person's breathing is interrupted during sleep. If left untreated, sleep apnea can increase the risk of health problems, such as high blood pressure, stroke, heart failure, irregular heartbeats, and heart attacks, diabetes, depression, worsening of ADHD, headaches. Depending on the cause and the level of apnea, there are different methods of treatment and the goal of treatment is to normalize breathing during sleep. Treatment options for obstructive sleep apnea include: Continuous Positive Airflow Pressure (CPAP), other breathing devices, oral appliances, implants and surgery.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 8: Cystic Fibrosis

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time and it affects the cells that produce mucus, sweat and digestive juices. It is caused by a change, or mutation, in a gene called CFTR (cystic fibrosis transmembrane conductance regulator). This gene controls the flow of salt and fluids in and out of the cells. The thick and sticky mucus associated with cystic fibrosis clogs the tubes that carry air in and out of the lungs. This can cause signs and symptoms such as persistent cough that produces thick mucus, wheezing, breathlessness, exercise intolerance, repeated lung infections, inflamed nasal passages or a stuffy nose. Cystic fibrosis is one of the leading causes of bronchiectasis, a condition that damages the airways and this makes it harder to move air in and out of the lungs and clear mucus from the airways.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 9: Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease isolated to the lung. IPF is a type of interstitial lung disease, which is a group of 200 diseases with similar symptoms but different causes. Symptoms of Idiopathic pulmonary fibrosis develops gradually and may not be noticed until the disease is well-established. IPF affects each person differently and the disease progresses at varying rates and it primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and does not affect the airways or blood vessels directly.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 10: Alpha 1 Antitrypsin Deficiency & COPD

Alpha-1 antitrypsin deficiency is a genetic disorder that is passed on in families and affects the lungs, liver and skin. When this condition affects the lungs, it causes COPD. There is no cure, but treatment can help people with Alpha-1 antitrypsin deficiency manage their symptoms and live a better life. The preliminary symptoms are shortness of breath following mild activity, reduced ability to exercise, and wheezing. Other signs and symptoms include unintentional weight loss, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Affected individuals often develop emphysema, which is a lung disease caused by damage to the small air sacs in the lungs. Alpha-1 antitrypsin deficiency accounts for 1 to 2% of all cases of chronic obstructive pulmonary disease.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 11: Pathology and Clinical Management of COPD

The predominant pathologic changes of COPD are found within the airways; however, changes are seen within the lung parenchyma and pneumonic vasculature. In an individual, the pattern of pathologic changes depends on the underlying illness (e.g., bronchitis, emphysema, alpha-1 antitrypsin deficiency), presumably individual susceptibility, and illness severity. High resolution computerized axial tomography can assess lung parenchyma, airways, and pneumonic vasculature. About 62 % of patients with moderate to severe COPD report variability in symptoms (e.g., dyspnea, cough, sputum, wheezing, or chest tightness) over the course of the day or week-to-week; morning is usually the worst time of day. An effective COPD management objective includes four components: assess and monitor the disease; reduce the risk factors; manage and stabilize COPD; manage the exacerbations. The most important factor for the COPD is cigarette smoking. The clinical management techniques involved to reduce the exacerbation of these factors that affect COPD must be developed in an efficient way.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 12:  Pulmonary Rehabilitation

Pulmonary Rehabilitation is an exclusive program for education and exercise that helps to manage the breathing problems, increase the alveolar capacity for breathing and the energy of the individual and reduces the breathlessness. Pulmonary rehabilitation can help to gain strength, reduce symptoms of anxiety or depression, and make it easier to manage routine activities, work, and outings or social activities.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 13: Diagnosis and Treatment of COPD

The main test for diagnosing COPD is a lung function test called spirometry which involves the use of a machine called a spirometer that measures how much air you are able to move by taking a deep breath in and out, and how quickly you are able to do so. Arterial blood gas analysis is second important test in diagnosing COPD. This test measures how much oxygen and carbon dioxide are present in the blood. A high percentage of carbon dioxide in the blood can be a sign of poorly functioning lungs. The important methods of treatment are pharmacotherapy and smoking cessation, while pulmonary rehabilitation, long-term oxygen therapy, and surgery may be considered in selected patients. Steroids, inhalers and antibiotics may be prescribed to treat various symptoms of COPD. Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival rate of persons suffering with COPD. Hence, smoking cessation should be the top priority in the treatment of COPD.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 14: Digital Health in Respiratory Care

Everyday life is increasingly influenced by digitization. Digital health technology promises to facilitate a patient-centered care model for the management of COPD by empowering patients to self-manage effectively and presently, it is not widely used in medicine. For pulmonology, digitization offers opportunities and risks in different areas like obstructive lung diseases, thoracic oncology, pulmonary rehabilitation, sleep medicine, home mechanical ventilation, and in intensive care medicine. One of the opportunities is that the use of new technologies such as medical apps and the analysis of this new support make it possible to better understand and manage diseases. One of the key advantages is the use of "big data" for displaying dynamic behavior to better understand disease processes, and to optimize patient management by using analytic techniques such as machine learning. Risks to be considered are data privacy and security as well as the use of artificial intelligence. Strategies used to date include approaches to monitoring and improving adherence, such as electronic inhalers, text messaging and reminders, and self-management tools.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 15: Lung Cancer Diagnosis & Treatment

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably which leads to the growth of tumors that reduce a person's ability to breathe. Symptoms of lung cancer include appetite loss, changes to a person's voice, such as hoarseness, frequent chest infections, such as bronchitis or pneumonia, lingering cough that may start to get worse, shortness of breath, unexplained headaches, weight loss and wheezing. Early diagnosis of lung cancer can be lifesaving because lung cancer cells can travel to other areas of the body before a doctor detects them in the lungs. If metastasis has taken place, it makes treating the disease much more difficult. Treatment for lung cancer depends on its location and stage, as well as the overall health of the individual. Possible treatments include surgery, chemotherapy, radiation therapy and targeted therapy.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Market Analysis

Globally, asthma and COPD are one of the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. They are either genetically acquired or caused due to several environmental factors. The global market for Asthma & COPD has been analyzed based on drugs and devices which are used for these diseases. Currently, North America leads the global market for asthma & COPD drugs and devices, and it was followed by Europe in terms of market capitalization. Growing aging population along with increasing automotive and industrial exhaust gases have remained the key drivers for the global asthma and COPD market. Degrading air quality near the industrial areas has led to the increased incidence of asthma in the low-income population in the emerging economies of China, India, Brazil and Russia.

COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risks such as smoking, pollution is not addressed. There is a rise in the prevalence of asthma and COPD in both developed and developing countries. In developed countries, the rise in prevalence is mainly due to lifestyle change such as smoking, while in developing countries rise is observed due to presence of most polluted cities in the world and inclusion of smoking in day-to-day lifestyle. Global COPD drugs market size will grow by almost USD 3.52 billion during 2019-2023, at a CAGR close to 4% due to the success of combination therapies.



Organizing Committee
OCM Member
Michael J. Simoff
Director of Bronchoscopy and Interventional Pulmonology, as well as Director of Lung Cancer Screening for HFHS
Wayne State University
Detroit, USA
OCM Member
Guang-Hui Dong
Chair of Department. Professor of Environmental Health, Sun Yat-sen University, Department of Environmental and Occupational Health
Sun Yat-sen University
Guangzhou, China
OCM Member
Jan De Backer
CEO, Fluidda nv
New York, USA
OCM Member
Bushra Mina
Section Chief, Lenox Hill Hospital, New York, Pulmonary Medicine at Lenox Hill Hospital
Lenox Hill Hospital | Northwell Health's
New York, USA
OCM Member
Dr. John Klir
American International Medical University
Washington, USA
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date October 7-8, 2021
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality


    Join The Discussion

    Allied Academies Global Conference Directory

    Mail us at

    Program Manager
    copd@alliedmeetings.com
    Sponsorship or Exhibitor Opportunity
    copdsummit@outlook.com
    More details about sponsorship:sponsors@alliedacademies.com

    Terms and Conditions

    Responsibility

    Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

    Insurance

    Registration fees do not include insurance of any kind.

    Transportation

    Please note that any (or) all transportation and parking is the responsibility of the registrant.

    Press/Media

    Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies Ltd is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

    Requesting an Invitation Letter

    For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact copd@alliedglobalevents.com to request a personalized letter of invitation.

    Regarding refunds, all bank charges will be for the registrants account.

    Cancellation, Postponement and Transfer of Registration

    All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

    • Within 90-60 days of Conference: Eligible for 50% of payment Refund
    • Within 60 days of Conference: Not eligible for Refund
    • E-Poster Payments will not be refunded.

    Cancellation Policy

    If Allied Academies Group cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Group event which must occur within one year from the date of cancellation.

    Postponement

    If Allied Academies Group postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Ltd event which must occur within one year from the date of postponement.

    Transfer of registration

    All fully paid registrations are transferable to other persons from the same organization if the registered person is unable to attend the event. Transfers must be made by the registered person in writing to finance@alliedacademies.com
    Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

    Registration can be transferred to one conference to another conference of Allied Academies Ltd if the person is unable to attend one of the conferences.

    However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

    The transferred registrations will not be eligible for Refund.

    Visa Information

    Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

    Allied Academies Ltd will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

    Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies Ltd, including the inability to obtain a visa.

    Refund Policy

    If the registrant is unable to attend and is not able to transfer his/her participation to another person or event, then the following refund arrangements apply:

    Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy in following slabs-

    Accommodation Cancellation Policy

    Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies Ltd will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

    Highlights from last year's Convention

    Authorization Policy

    Copyright © 2021-2022 Allied Academies, All Rights Reserved.